ENDPOINTS

Drug packaging manufacturers brace for impact as EU che...

The European Union’s proposed ban on “forever chemicals” is expected to become l...

AstraZeneca buys FibroGen’s China unit for local contro...

AstraZeneca is furthering its presence in China by gaining complete control of F...

BridgeBio’s heart disease drug Attruby sails past presc...

BridgeBio revealed Thursday that prescriptions for its recently approved rare he...

EG 427 collects €27M in Series B to advance overactive ...

A French biotech focused on developing genetic medicines for neurological condit...

Can amylin drugs take over from GLP-1s in obesity? Part...

Zealand Pharma investors eager for news of a partnering deal for the Danish grou...

Updated: Federal government defends lab-developed test ...

An attorney for the federal government said the FDA “acted well within its autho...

Hims buys at-home testing company Trybe Labs

Hims & Hers bought an at-home lab testing company as it branches out into other ...

Government is set to address its lab-developed test rul...

Attorneys for the government and laboratory diagnostics trade groups have gather...

Nvidia, Arc Institute release Evo 2, a new AI model for...

Nearly a year ago, bioengineering professor Patrick Hsu asked: “Is DNA all you n...

Ascletis’ obesity pill looks similar to Roche’s drug, e...

Ascletis Pharma’s oral GLP-1 allowed patients in an early-stage obesity trial to...

Another Chinese biotech files to go public in Hong Kong...

Plus, news about Harmony Biosciences and Reverb Therapeutics: Genuine Biotec...

Pfizer CEO says Trump opportunities outweigh risks

WASHINGTON — Over 500 pharma executives, lobbyists, consultants and other indust...

Biotech is still trying to make CRISPR a success

This is the first in a series of stories from Endpoints News that looks at the f...

FDA places two Indian manufacturers on import alerts ov...

The FDA has prohibited two API manufacturers from shipping products to the US, w...

RFK Jr. readies review of childhood vaccine schedule af...

In his first speech to staff as newly confirmed HHS Secretary, Robert F. Kennedy...

Epitopea secures R&D deal with Merck for tumor-specific...

Epitopea has inked a license and research collaboration with Merck to discover n...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.